Pharmaceuticals

Global Prostate Cancer Drugs Market Set To Expand To $2.61 Billion By 2030 At 11% CAGR

May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Prostate Cancer Drugs Market Expected To Change From 2026 To 2030?

The prostate cancer drugs market has experienced substantial growth in recent times. Projections indicate it will expand from $19.51 billion in 2025 to $20.54 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 5.3%. Historically, this expansion is attributable to factors such as an aging male population, increased prostate cancer screening, widespread hormone therapy adoption, the expansion of oncology clinics, and rising cancer awareness.

The prostate cancer drugs market size is projected to experience robust expansion over the coming years. Its value is anticipated to reach $26.15 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.2%. This anticipated growth during the forecast period stems from factors such as an increase in targeted and immunotherapy medications, a rising prevalence of advanced prostate cancer cases, enhanced personalization of treatments, wider availability of healthcare, and increased expenditure on oncology. Key developments expected in this period include the increased application of hormonal therapy in initial treatments, greater uptake of targeted prostate cancer drugs, an intensified focus on castration-resistant prostate cancer, the broader implementation of combination therapy strategies, and an expansion of hospital-centric prostate cancer services.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2592&type=smp

Which Primary Drivers Are Impacting The Prostate Cancer Drugs Market Growth?

The increasing men geriatric population is expected to propel the growth of the prostate cancer drugs market going forward. This demographic refers to males aged 65 and older, who typically experience a higher prevalence of age-related health conditions and require specialized medical attention. The rise in this aging male population is attributed to improved healthcare access, declining mortality rates, and longer lifespans globally. This growing geriatric male population supports the prostate cancer drugs market by expanding the pool of patients needing hormonal therapies, immunotherapies, chemotherapy, and targeted medicines for disease management and enhanced survival. For instance, in February 2025, according to the World Health Organization, a Switzerland-based international public health organization, global life expectancy at birth reached 73.3 years in 2024, and the number of people aged 60 and older worldwide is projected to increase from 1.1 billion in 2023 to 1.4 billion by 2030. Therefore, the increasing men geriatric population is driving the growth of the prostate cancer market.

How Is Segmentation Applied In The Prostate Cancer Drugs Market Segment Analysis?

The prostate cancer drugs market covered in this report is segmented –

1) By Type: Hormone Sensitive Prostate Cancer, Hormone Refractory Prostate Cancer

2) By Therapy: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy

3) By End User: Hospitals, Clinics, Other End-Users

Subsegments:

1) By Hormone Sensitive Prostate Cancer: Early-Stage Prostate Cancer, Locally Advanced Prostate Cancer, Metastatic Prostate Cancer

2) By Hormone Refractory Prostate Cancer: Castration-Resistant Prostate Cancer (CRPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)

What Trends Are Transforming The Prostate Cancer Drugs Market?

Leading firms in the prostate cancer drugs market coordinate their initiatives to launch novel products and secure regulatory approval, aiming to boost their market earnings. The journey of drug creation and its subsequent approval is protracted and intricate, making it crucial for pharmaceutical developers to grasp the regulatory frameworks and commercialization strategies required to guarantee adequate safety and efficacy. A case in point is June 2023, when UK-based AstraZeneca PLC and US-based Merck & Co. Inc. jointly declared that the United States Food and Drug Administration’s (USFDA), a US federal agency under the Department of Health and Human Services, had approved LYNPARZA (olaparib) Plus Abiraterone and Prednisone or Prednisolone for the treatment of adult patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC). LYNPARZAplus abi/pred exhibited notable clinical advancements in both radiographic progression-free survival (rPFS) and overall survival (OS) when contrasted with abi/pred used alone in patients with BRCAm mCRPC. This finding stemmed from an exploratory subgroup analysis of the Phase 3 PROpel trial, which was instrumental in securing this approval.

Who Are The Companies Participating In The Prostate Cancer Drugs Market Environment?

Major companies operating in the prostate cancer drugs market are Astellas Pharma Inc., AstraZeneca PLC, Johnson & Johnson, Sanofi S.A., Bayer AG, Abbott Laboratories, Pfizer Inc., Novartis International AG, F. Hoffmann-La Roche Ltd., Tolmar Inc., AbbVie Inc., Siemens Healthineers AG, Genomic Health Inc., OPKO Health Inc., Siemens Healthcare GmbH, MDxHealth SA, Myriad Genetics Inc., Janssen Biotech Inc., Clovis Oncology Inc., Merck Sharp & Dohme Corp., Dendreon Corporation, Ferring Pharmaceuticals Inc., Ipsen Biopharmaceuticals Inc., Merck & Co. Inc., Eli Lilly and Company Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novartis AG, Amgen Inc., Regeneron Pharmaceuticals Inc., Exelixis Inc.

Get The Full Prostate Cancer Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

Which Region Is The Largest In The Prostate Cancer Drugs Market?

North America was the largest region in the prostate cancer drugs market in 2025. Middle East is expected to be the fastest-growing region in the prostate cancer drugs market during the forecast period. The regions covered in the prostate cancer drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Prostate Cancer Drugs Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

Browse Through More Reports Similar to the Global Prostate Cancer Drugs Market 2026, By The Business Research Company

Prostate Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

Metastatic Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/metastatic-cancer-drugs-global-market-report

Bladder Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/bladder-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795